Utilization of thromboelastography and a low molecular weight heparin anti-Xa assay for guidance in apixaban reversal: A case report
| Autor: | George J. Philip, Tori R. Adams, Tessa R. Reynolds, David A. Moran, Brian W. Gilbert |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Pyridones medicine.drug_class Low molecular weight heparin Guidelines as Topic Hemorrhage Bioinformatics 03 medical and health sciences 0302 clinical medicine medicine Coagulopathy Humans Aged 80 and over medicine.diagnostic_test business.industry 030208 emergency & critical care medicine General Medicine Heparin Heparin Low-Molecular-Weight Bleed medicine.disease Thromboelastography Thrombelastography Emergency Medicine Pyrazoles Apixaban business Factor Xa Inhibitors medicine.drug |
| Zdroj: | The American Journal of Emergency Medicine. 37:1991.e1-1991.e3 |
| ISSN: | 0735-6757 |
| DOI: | 10.1016/j.ajem.2019.158369 |
| Popis: | Reversal of oral factor Xa (FXa) inhibitors, such as apixaban, remains a controversial topic. However, the controversy goes beyond what reversal agent to utilize. Often times these patients present with an acute major bleed and are difficult to assess whether reversal is warranted or not. Furthermore, it is difficult to assess whether reversal was successful in a timely manner. A paucity of literature exists regarding the utilization of low molecular weight heparin (LMWH) anti-Xa assays and thromboelastography for identifying coagulopathies associated with oral FXa inhibitors. We report a case of apixaban induced coagulopathy utilizing thromboelastography and a LMWH anti-Xa assay as a guide for reversal. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect